Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Forest Laboratories, Inc.

http://www.frx.com

Latest From Forest Laboratories, Inc.

A Decade At The Top: Lupin MD On Listing Adjacencies, Creating Health Care Continuum

As family-led firms go through a churn in India, Lupin’s MD Nilesh Gupta speaks about adding value via adjacencies to the legacy business, building digital interfaces and a healthcare continuum for patients. In an interview with Scrip, he also emphasized Lupin promoters are neither interested in selling their own stake nor in acquiring that of Cipla’s promoters.

C-Suite Speaks Commercial

A Decade At The Top: Lupin MD On Listing Adjacencies, Creating Healthcare Continuum

As family-led firms go through a churn in India, Lupin’s MD Nilesh Gupta speaks about adding value via adjacencies to the legacy business, building digital interfaces and a healthcare continuum for patients. In an interview with Scrip, he also emphasized Lupin promoters are neither interested in selling their own stake nor in acquiring that of Cipla’s promoters.

Commercial Leadership

India M&A Hourglass: Control Deals, ‘FOMO’, Monetization Calls At Family-Owned Firms

The founder and MD of investment bank Candle Partners reflects on key pharma M&A trends over the years and the shape of things to come including private equity action and how family-owned firms are weighing monetization and diversification options.

Commercial M & A

Will More Indian Family-Owned Firms Hand Over The Baton To PEs?

Private equity firms are among those believed to be in the fray for a stake in India's Cipla, a company with a rich legacy and steeped in history. It’s an ideal case study for buyout funds, according to an investment banker.

Deals India
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Aptalis Pharma Inc. (Axcan Pharma, Inc.
    • Eurand N.V.
    • Mpex Pharmaceuticals, Inc.)
    • Cerexa, Inc.
    • Clinical Data, Inc.
UsernamePublicRestriction

Register